Please login to the form below

Launch excellence

In the April edition of PME, Cheryl Harrison Doyle, Global Asset Strategy Director at Lucid Group discusses the need to take a more considered, outcomes-led approach when launching new medicines today.

With a rapidly changing clinical, economic and regulatory environment, the launch of new products has catapulted the pharmaceutical industry into greater complexity and pressure than ever before. Historically, new asset launches have been a tale of two halves: a hit or miss. Between 2009 and 2017, 40% of worldwide drug launches failed to meet their 2-year sales forecasts, according to McKinsey & Company1. Taking into consideration the evolving environment, there has never been a greater need for new models to navigate the path of an asset to market.

Over the past 15 years, our clients have regularly come to us to help them execute their launch plans. Often the ask is around launch readiness and activation, with a focus on tactical execution. In this article, we discuss the need to get ahead of tactical planning and demonstrate the role of ‘pre-launch asset preparedness’, to ensure we maximise the potential of specialised medicines in this highly complex environment.

You can read the full article online here or download it so you can read it later here.

If you’re planning a launch and looking for some advice, get in touch! We’re hosting free launch-strategy clinics throughout May and June. Contact Cheryl Harrison Doyle or Clare Reynolds for more details.
07818 568882
07501 989799

12th April 2022



Company Details

Lucid Group Communications Limited

0345 0536671

Contact Website

First Floor, Jubilee House
Third Avenue
Globe Park

Latest content on this profile

My Lucid journey from PMW to Head of Medical
Working in Medical Communications has never been about the nine to five. Fusing science and language in the service of both clients and patients, this is typically a fast paced and demanding industry, but one which offers enviable flexibility, variety and intellectual challenge. Leading agency Lucid Group prides itself on the many growth and development opportunities it offers its people. In this article, Katherine Duxbury, Lucid’s Head of Medical, reflects upon her own bespoke working journey over the past 12 years and explains how creativity, collaboration and a passion for science have led to a rewarding, stimulating and self-curated career.
Lucid Group Communications Limited
Listen, learn and lift off

Lucid Group Communications Limited
Launch excellence

Lucid Group Communications Limited
Meet The Lucid Group Talent Team
Meet our talent team, they're here to help and transform your career.We have some exciting roles at all levels in account management and medical writing.If you choose to take your career to the next level with us, you can be assured that you'll have a whole group of people here cheering you on.So, if you’re feeling stuck or unfulfilled in your current role and looking for a company that will provide the personal and career development you need, please check out our open roles here: contact one of our talent acquisition managers for a chat:Ellen Field Assoc CIPDElaine DowneyJon TurnerDaniel Newbury
Lucid Group Communications Limited
Extraordinary lives: advancing change in rare diseases (Part 2)

Lucid Group Communications Limited
Extraordinary lives: advancing change in rare diseases (Part 2)
In support of Rare Disease Day, we're excited to launch part 2 of our video series; Extraordinary lives: advancing change in rare diseases.Why is raising awareness of rare diseases so important?Because 300 million people worldwide are living with a rare disease. This means that, collectively, the number of people living with a rare disease is equivalent to the population of the world's third-largest country (USA).While we have come a long way since the inception of Rare Disease Day, there's still plenty of work to do.Part 2 of this series focuses on important topics including the role of technology and the opportunities it presents for the rare disease community. The panel also hold captivating insights on how the pandemic has impacted the use of related digital technologies, the role of gene therapy, the major challenges and successes for pharma companies in supporting the rare disease community over the last 13 years, and much, much more.If you’d like to know more about the work we do in rare diseases or would like advice on any healthcare communication challenges please get in touch with Clare Reynolds on LinkedIn or by email: clare.reynolds@wearelucidgroup.comAbout Lucid GroupFounded in 2007, Lucid Group is a global multi-capability healthcare consultancy with core expertise in medical strategy, healthcare communications, creative and brand strategy, motion, digital and technology, behaviour change, metrics, and data analytics.  We partner with the pharma and biotech industry, delivering life-transforming value with connected capabilities to create pioneering solutions that change behaviour, improve clinical practice and advance health outcomes.  Transforming lives. Always.
Lucid Group Communications Limited